Neurotoxic amyloidogenic peptides in the proteome of SARS-COV2: potential implications for neurological symptoms in COVID-19
- Author(s)
- Charnley, M; Islam, S; Bindra, GK; Engwirda, J; Ratcliffe, J; Zhou, J; Mezzenga, R; Hulett, MD; Han, K; Berryman, JT; Reynolds, NP;
- Journal Title
- Nature Communications
- Publication Type
- Research article
- Abstract
- COVID-19 is primarily known as a respiratory disease caused by SARS-CoV-2. However, neurological symptoms such as memory loss, sensory confusion, severe headaches, and even stroke are reported in up to 30% of cases and can persist even after the infection is over (long COVID). These neurological symptoms are thought to be produced by the virus infecting the central nervous system, however we don't understand the molecular mechanisms triggering them. The neurological effects of COVID-19 share similarities to neurodegenerative diseases in which the presence of cytotoxic aggregated amyloid protein or peptides is a common feature. Following the hypothesis that some neurological symptoms of COVID-19 may also follow an amyloid etiology we identified two peptides from the SARS-CoV-2 proteome that self-assemble into amyloid assemblies. Furthermore, these amyloids were shown to be highly toxic to neuronal cells. We suggest that cytotoxic aggregates of SARS-CoV-2 proteins may trigger neurological symptoms in COVID-19.
- Keywords
- *COVID-19/complications; Humans; Peptides; Proteome; RNA, Viral; SARS-CoV-2; Post-Acute COVID-19 Syndrome
- Department(s)
- Laboratory Research
- PubMed ID
- 35697699
- Publisher's Version
- https://doi.org/10.1038/s41467-022-30932-1
- Open Access at Publisher's Site
https://doi.org/10.1038/s41467-022-30932-1- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-10-16 03:58:13
Last Modified: 2024-10-16 03:59:23